RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer

The genetic components of the RB:CDK:cyclin:p16 tumor suppressor pathway undergo mutational and epigenetic alterations in a wide range of human cancers and serve as critical targets for inactivation by the transforming oncoproteins of several DNA tumor viruses. Lung cancer has been a useful model system for these studies as it was the first tumor to demonstrate an important role for RB in the genesis of a common adult malignancy and was also the first human cancer to demonstrate genetic evidence for a multi-component RB:p16 tumor suppressor pathway. Lung tumorigenesis, however, is a complex disease process that requires longstanding carcinogen exposure in order to acquire somatic alterations at many distinct genetic loci. Understanding the multifunctional properties of RB to regulate cell proliferation, differentiation, and apoptosis and how they relate to the sequential accumulation of other clonal gene defects will be essential in order to understand the specific patterns of gene inactivation observed in different subtypes of lung cancer and to fulfill the promise of ‘molecular target’ therapeutics.

[1]  J. Harbour,et al.  The Rb/E2F pathway: expanding roles and emerging paradigms. , 2000, Genes & development.

[2]  Rene H Medema,et al.  Rescue of Cyclin D1 Deficiency by Knockin Cyclin E , 1999, Cell.

[3]  Phang-lang Chen,et al.  Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation , 1989, Cell.

[4]  B. Ponder,et al.  Molecular Genetics of Cancer , 1992, Nature Medicine.

[5]  A. Bradley,et al.  Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis , 1992, Nature.

[6]  J. Herman,et al.  In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Minna,et al.  Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. , 1999, Journal of the National Cancer Institute.

[8]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[9]  Molecular pathogenesis of lung cancer. , 2002 .

[10]  Rosalie C Sears,et al.  Signaling Networks That Link Cell Proliferation and Cell Fate* , 2002, The Journal of Biological Chemistry.

[11]  Peggy J. Farnham,et al.  Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties , 1992, Cell.

[12]  L. Donehower,et al.  Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. , 1995, Cancer research.

[13]  R. Weinberg,et al.  Effects of an Rb mutation in the mouse , 1992, Nature.

[14]  T. Jacks,et al.  Cooperative tumorigenic effects of germline mutations in Rb and p53 , 1994, Nature Genetics.

[15]  J. Decaprio,et al.  The J Domain of Simian Virus 40 Large T Antigen Is Required To Functionally Inactivate RB Family Proteins , 1998, Molecular and Cellular Biology.

[16]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[17]  F. Hirsch,et al.  Epidermal growth factor receptor family in lung cancer and premalignancy. , 2002, Seminars in oncology.

[18]  J. Yokota,et al.  Identification and characterization of families with aggregation of lung cancer. , 1998, Japanese journal of clinical oncology.

[19]  Chun-Ming Huang,et al.  SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family , 1989, Cell.

[20]  P. K. Davis,et al.  Vivo Cyclin-dependent Kinase Complexes in 1 Tumor Suppressor Protein by G Differential Regulation of Retinoblastoma , 2001 .

[21]  Molecular genetics of cancer. , 1992 .

[22]  S. Salama,et al.  Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. de Leiva,et al.  Ras Oncogene Mutations in Thyroid Tumors: Polymerase Chain Reaction‐Restriction‐Fragment‐Length Polymorphism Analysis from Paraffin‐Embedded Tissues , 1996, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[24]  W. Kaelin,et al.  Role of the retinoblastoma protein in the pathogenesis of human cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Barbacid,et al.  Cyclin D-dependent kinases, INK4 inhibitors and cancer. , 2002, Biochimica et biophysica acta.

[26]  S. Steinberg,et al.  Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. , 1995, Journal of the National Cancer Institute.

[27]  James M. Roberts,et al.  The p21Cip1 and p27Kip1 CDK ‘inhibitors’ are essential activators of cyclin D‐dependent kinases in murine fibroblasts , 1999, The EMBO journal.

[28]  F. Marincola,et al.  Sequential 5-Aza-2′-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1 , 2001, Journal of immunotherapy.

[29]  F. Kaye,et al.  RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer , 1998, Oncogene.

[30]  Wen-Hwa Lee,et al.  Expression and amplification of the N-myc gene in primary retinoblastoma , 1984, Nature.

[31]  David M. Livingston,et al.  The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element , 1989, Cell.

[32]  J. Bartek,et al.  Pathways governing G1/S transition and their response to DNA damage , 2001, FEBS letters.

[33]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[34]  Wen-Hwa Lee,et al.  The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity , 1987, Nature.

[35]  Steven F. Dowdy,et al.  Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes , 2002 .

[36]  M. Tucker,et al.  Hereditary retinoblastoma and risk of lung cancer. , 2000, Journal of the National Cancer Institute.

[37]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[38]  E. Sausville,et al.  Preclinical and clinical development of cyclin-dependent kinase modulators. , 2000, Journal of the National Cancer Institute.

[39]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[40]  F. Hirsch,et al.  HER2/neu expression in malignant lung tumors. , 2002, Seminars in oncology.

[41]  G. Draper,et al.  Non-ocular cancer in relatives of retinoblastoma patients. , 1989, British Journal of Cancer.

[42]  Jonathan A. Cooper,et al.  RB and the cell cycle: Entrance or exit? , 1989, Cell.

[43]  J. Herman,et al.  A bird's eye view of global methylation , 2000, Nature Genetics.

[44]  R. Makuch,et al.  myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines. , 1988, Cancer research.

[45]  F. Kaye,et al.  A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Minna,et al.  Origin of human small cell lung cancer. , 1985, Science.

[47]  T. Jacks,et al.  The retinoblastoma gene family in differentiation and development , 1999, Oncogene.

[48]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[49]  J. Minna,et al.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. , 1988, Science.

[50]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[51]  C. Eng,et al.  Mortality From Second Tumors Among Long-Term Survivors of Retinoblastoma , 1993 .

[52]  C. D. Edwards,et al.  Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. , 1995, Cancer research.

[53]  S. Schröder,et al.  Absence of H- and K-ras oncogene mutations in sporadic medullary thyroid carcinoma. , 2012, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[54]  J. Yokota,et al.  How many tumor suppressor genes are involved in human lung carcinogenesis? , 1999, Carcinogenesis.

[55]  F. Kaye,et al.  CDKN2 in HPV‐positive and HPV‐negative cervical‐carcinoma cell lines , 1995, International journal of cancer.

[56]  F. Kaye,et al.  Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer , 2000, Oncogene.

[57]  R. Weinberg,et al.  Physical interaction of the retinoblastoma protein with human D cyclins , 1993, Cell.

[58]  D. Sidransky,et al.  Rates of p16 (MTS1) mutations in primary tumors with 9p loss. , 1994, Science.

[59]  F. Kaye,et al.  Identification of cellular proteins that can interact specifically with the T/ElA-binding region of the retinoblastoma gene product , 1991, Cell.

[60]  N. Tommerup,et al.  Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[61]  A. El‐Naggar,et al.  Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. , 1997, The American journal of pathology.

[62]  G. Peters,et al.  Lack of cyclin D‐Cdk complexes in Rb‐negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. , 1995, The EMBO journal.

[63]  N. Dyson,et al.  Retinoblastoma protein partners. , 2001, Advances in cancer research.

[64]  Peter A. Jones,et al.  P16 gene in uncultured tumours , 1994, Nature.

[65]  R. Momparler,et al.  Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. , 2001, Lung cancer.

[66]  Stephen H. Friend,et al.  A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma , 1986, Nature.

[67]  M. Skolnick,et al.  A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.

[68]  J. Easton,et al.  Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. , 1998, Cancer research.

[69]  J. Battey,et al.  Human small-cell lung cancers show amplification and expression of the N-myc gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[70]  P. Adams.  Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. , 2001, Biochimica et biophysica acta.

[71]  R. Weinberg,et al.  Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[72]  A. Gazdar,et al.  K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. , 1994, Cancer research.

[73]  D. Abramson,et al.  Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. , 2001, Ophthalmology.

[74]  M Terada,et al.  Loss of heterozygosity on chromosomes 3, 13, and 17 in small-cell carcinoma and on chromosome 3 in adenocarcinoma of the lung. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[75]  S. Baylin,et al.  v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line. , 1990, The Journal of clinical investigation.

[76]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[77]  Liang Zhu,et al.  Requirement of Cyclin E-Cdk2 Inhibition in p16INK4a-Mediated Growth Suppression , 1998, Molecular and Cellular Biology.

[78]  B. Dynlacht,et al.  Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition , 1995, Nature.